Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior
- PMID: 41077262
- DOI: 10.1016/j.pnpbp.2025.111522
Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior
Abstract
Psilocybin and lisuride are 5-HT2A receptor agonists, but only psilocybin elicits the head twitch response (HTR) in rodents, a behavior commonly used as a proxy for hallucinogenic activity. This study aimed to compare their effects on serotonin (5-HT) and dopamine (DA) neuronal activity, as well as related behavioral outcomes, to elucidate the mechanisms underlying their divergent effects. Adult male C57BL/6N mice were administered intraperitoneal injections of psilocybin (0.3-3 mg/kg), lisuride (0.1-0.5 mg/kg), or vehicle. In vivo electrophysiological recordings were performed in the dorsal raphe nucleus (DRN) and substantia nigra (SN) to monitor 5-HT and DA neuronal firing. MDL 100907 (0.2 mg/kg) pretreatment was used to determine 5-HT2A receptor specificity. Behavioral assessments included HTR testing 10 min post-injection, followed by either the forced swim test (FST), open field test (OFT), or elevated plus maze (EPM) at 20 min post-injection. Psilocybin-induced inhibition, but not lisuride-induced inhibition, of 5-HT neuron firing was blocked by MDL 100907. Both drugs reduced DA neuron firing, however, lisuride's effect was more sensitive to 5-HT2A receptor antagonism. Psilocybin elicited HTR, while lisuride did not. In the FST, only high-dose lisuride reduced immobility time. Both drugs reduced locomotor activity in the OFT and EPM. Principal Component Analysis (PCA) sufficiently separated the effects of each drug from each other, indicating distinct effect profiles. Although both drugs target 5-HT2A receptors, they engage distinct neurobiological pathways. Psilocybin produces psychedelic-like, 5-HT-dominant effects, whereas lisuride displays DA-linked improvements in coping behavior, informing future development of serotonergic therapeutics.
Keywords: Antidepressant; Anxiolytic; Dopamine; Electrophysiology; Lisuride; Psilocybin; Serotonin.
Copyright © 2025. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest GG received grants from Diamond Therapeutics Inc. DDG was a consultant for Diamond Therapeutics Inc. JS is a consultant for Diamond Therapeutics Inc. The remaining authors have no conflicts of interest. We wish to disclose the following competing interests to the journal for transparency. Dr. Gabriella Gobbi has received grants from Diamond Therapeutics Inc. Dr. Danilo De Gregorio and Dr. Jeffery Sprouse have served as consultants for Diamond Therapeutics Inc. These affiliations have not influenced the study's design, analysis, or interpretation. The remaining authors declare no competing interests.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
